These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical study on treatment of recurrent genital herpes by Huangqi Fuzheng Decoction].
    Author: Shi YJ, Du XX, Zhang CH.
    Journal: Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 Mar; 28(3):222-4. PubMed ID: 18476421.
    Abstract:
    OBJECTIVE: To observe the clinical efficacy of Huangqi Fuzheng Decoction (HQFZD) in treating recurrent genital herpes (RGH) and its influence on related cytokines in peripheral blood. METHODS: Eighty-four patients with RGH were randomly assigned to 3 groups, the treated group treated with HQFZD (31 cases), the control group A (25 cases) treated with Aciclovir, and the control group B (28 cases) treated with Aciclovir plus interferon. The course of treatment was 3 weeks for all. The relapse rate was estimated at 6 months after treatment, and levels of IL-4, IL-10, IL-12 and IL-18 in all patients were detected before and after treatment using double-sandwich ELISA. RESULTS: All patients were cured after treatment. The relapse rate in the treated group and the control group B was lower than that in the control group A (P < 0.01) but insignificant difference was shown between the former two groups. Before treatment, patients' serum levels of IL-4 and IL-10 were significantly higher while those of IL-12 and IL-18 were lower than the normal range (P < 0.01). The abnormal change aforementioned reversed after treatment in the treated group and the control group B (P < 0.05 or P < 0.01), showing a superior effect to that in the control group A (P < 0.01). CONCLUSION: HQFZD can reduce the relapse rate of RGH without obvious adverse reaction, and it could also enhance the immunity of the patients.
    [Abstract] [Full Text] [Related] [New Search]